Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.40 |
| ▸ | PDE5A | O76074 | 5/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 7/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039569 | 0.99 | PDE4B (0.40) | PDE4BPDE5APDE3AADORA1HRH3 | |
| SCHEMBL7034665 | 0.99 | PDE4B (0.40) | PDE4BPDE5APDE3AADORA1HRH3 | |
| SCHEMBL7041201 | 0.99 | PDE4B (0.40) | PDE4BPDE5APDE3AADORA1HRH3 | |
| SCHEMBL7036668 | 0.98 | PDE4B (0.40) | PDE4BPDE5APDE3AADORA1HRH3 | |
| SCHEMBL7042107 | 0.91 | PDE4B (0.39) | PDE4BPDE5APDE3AADORA1 | |
| SCHEMBL7151884 | 0.91 | PDE4B (0.39) | PDE4BPDE5APDE3AADORA1 | |
| SCHEMBL7039211 | 0.87 | PDE4B (0.37) | PDE4BPDE5APDE3AADORA1 | |
| SCHEMBL7038305 | 0.86 | PDE4B (0.39) | PDE4BPDE5APDE3AADORA1HRH3 | |
| SCHEMBL7040393 | 0.84 | PDE5A (0.44) | PDE4BPDE5APDE3AADORA1HRH3 | |
| SCHEMBL7038848 | 0.83 | PDE5A (0.43) | PDE4BPDE5APDE3AADORA1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003004494-A1 | PYRIDAZINONE COMPOUND AS ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-01-16 | — | — | WO | disclosed |